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Objective To evaluate the primary, secondary and combined resistance to five anti-
microbial agents of 2340 Helicobacter pylori isolates from 19 centers in 10 countries in
eastern Europe.
Methods Data were available for centers in Bulgaria, Croatia, the Czech Republic,
Estonia, Greece, Lithuania, Poland, Russia, Slovenia and Turkey. Susceptibility was
tested by agar dilution (seven countries), E test (five countries) and disk diffusion (three
countries) methods. Resistance breakpoints (mg/L) were: metronidazole 8, clarithromy-
cin 1, amoxicillin 0.5, tetracycline 4, and ciprofloxacin 1 or 4 in most centers. Primary and
post-treatment resistance was assessed in 2003 and 337 isolates respectively. Results for
282 children and 201 adults were compared.
Results Primary resistance rates since 1998 were: metronidazole 37.9%, clarithromycin
9.5%, amoxicillin 0.9%, tetracycline 1.9%, ciprofloxacin 3.9%, and both metronidazole and
clarithromycin 6.1%. Isolates from centers in Slovenia and Lithuania exhibited low
resistance rates. Since 1998, amoxicillin resistance has been detected in the southeastern
region. From 1996, metronidazole resistance increased significantly from 30.5% to 36.4%,
while clarithromycin resistance increased slightly from 8.9% to 10.6%. In centers in
Greece, Poland, and Bulgaria, the mean metronidazole resistance was slightly higher in
adults than in children (39% versus 31.2%, P> 0.05); this trend was not found for
clarithromycin or amoxicillin (P> 0.20). Post-treatment resistance rates exhibited wide
variations.
Conclusions In eastern Europe, primary H. pylori resistance to metronidazole is con-
siderable, and that to clarithromycin is similar to or slightly higher than that in western
Europe. Resistance to amoxicillin, ciprofloxacin and tetracycline was detected in several
centers. Primary and post-treatment resistance rates vary greatly between centers.
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I N T R O D U C T I O N
Resistance of Helicobacter pylori to metronidazole
has been associated with a drop in efficacy of 15–
50% for regimens involving nitroimidazoles; and
clarithromycin resistance has a higher negative
impact on treatment outcome, with a drop in
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efficacy from 92% to 50% in triple regimens includ-
ing newer macrolides [1–4]. Recently, the resis-
tance of H. pylori to amoxicillin, tetracycline and
ciprofloxacin has been recognized [3,5–8]. While
many studies have focused on H. pylori resistance
patterns worldwide, there are still few reports
concerning this topic in the eastern part of Europe.
The aim of this study was to evaluate the primary,
combined and post-treatment resistance preva-
lence to five antimicrobial agents of 2340 H. pylori
isolates from 19 centers in 10 eastern European
countries.
M A T E R I A L S A N D M E T H O D S
The distribution of H. pylori isolates among centers
is given in Table 1. Susceptibility testing was per-
formed with an agar dilution method in centers in
seven countries, with the E test in five countries,
and with a disk diffusion method in three coun-
tries. Two methods were used in centers in five
countries. Inocula of H. pylori, corresponding to
McFarland turbidity standard 2–4, and blood-
enriched Mueller–Hinton agar were used. Other
supporting media, such as brain–heart infusion
agar and Brucella agar enriched with blood, were
used in only three centers using the disk diffusion
method. Plates were incubated in micro-aerophilic
conditions at 37 8C for 2–3 (exceptionally 5) days.
The following resistance breakpoints were used:
metronidazole 8 mg/L, clarithromycin 1 mg/L,
amoxicillin 0.5 mg/L, tetracycline 4 mg/L, and
ciprofloxacin 1 or 4 mg/L for most centers. Break-
points for the disk diffusion method were 15 mm
for metronidazole, 15 or 20 mm for clarithromycin,
and 15 mm for amoxicillin.
Statistical analysis was performed by chi-square
without or with Yates’ correction, and chi-square
among several groups.
Prevalence of primary H. pylori resistance
Data on the prevalence of primary H. pylori resis-
tance in 1996–2000 were collected for 2003 clinical
isolates, 1371of them being evaluated since 1998.
Results obtained for centers in north–central
(Czech Republic and Poland), northeastern (Esto-
nia, Russia and Lithuania), south–central (Slovenia
and Croatia) and southeastern (Bulgaria, Greece
and Turkey) regions were compared [9–26] (pers.
Table 1 Distribution of H. pylori isolates
Study parameters MTZ CLA AMX TET CIP METþCLA
1. Primary resistance since 1996
No. of strains 2003 1973 1442 925 635 1041
No. of centers 119 18 17 9 8 8
No. of countries 110 9 8 6 5 5
2. Evolution of resistance since 1996
No. of strains 1353 1301 794 446 484 610
No. of strains isolated in 1996–97 515 461 388 204 250 287
No. of strains isolated in 1998–2000 838 840 406 242 234 323
No. of centers 10 10 12 3 5 4
No. of countries 5 5 5 2 3 3
3. Resistance in children/adults since 1998
No. of strains from children 282 282 282 168 168 243
No. of strains from adults 195 197 201 109 75 108
No. of centers 5 5 5 4 3 3
No. of countries 3 3 3 3 3 2
4. Post-treatment resistance
No. of strains 120 218 116
No. of centers 4 6 3
No. of countries 3 5 3
Secondary resistance
No. of strains 32 160
No. of centers 2 6
No. of countries 2 4
MTZ, metronidazole; CLA, clarithromycin; AMX, amoxicillin; TET, tetracycline; CIP, ciprofloxacin; METþCLA,
metronidazole and clarithromycin.
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comm.: A. Mentis; G. Gosciniak; M. Gubina; S.
Kalenic; L. Boyanova; K. Ivanova and M. Marina;
A. Aydin; V. Go¨ral; A. O¨zden; E. Rozynek and D.
Dzierz˙anowska).
Evolution of primary H. pylori resistance from
1996 to 2000
The evolution of primary resistance was evaluated
in 1353 H. pylori strains from centers in six coun-
tries (Table 1) [9,14–16,18,19,26] (pers. comm.: G.
Gosciniak; M. Gubina; S. Kalenic; L. Boyanova; K.
Ivanova and M. Marina; A. Aydin; V. Go¨ral; A.
O¨zden; E. Rozynek and D. Dzierz˙anowska). Resis-
tance rates were compared between strains iso-
lated in 1996–97 and those isolated in 1998–2000.
Resistance prevalence was also calculated for the
years at the beginning and the end of studies in
different centers.
Resistance patterns in children and adult
patients
Results obtained for children and adults in five
centers in three countries since 1998 were com-
pared [16–19] (pers. comm.: A. Mentis; G. Gosci-
niak; L. Boyanova; K. Ivanova and M. Marina; E.
Rozynek and D. Dzierz˙anowska). Of 282 children
aged 4–18 years, 52% were boys and 48% were
girls. The origin of pediatric strains was as follows:
36 children in Greece (55.6% boys and 44.4% girls)
aged 6–15 years (mean age 10.5 years) with symp-
toms of gastritis; 71 children in Bulgaria (46.5%
boys and 53.5% girls) aged 4–17 years with gas-
tritis (88.7%) or duodenal ulcer (11.3%); and 175
children in Poland (53.7% boys and 46.3% girls)
aged 6–18 years with dyspeptic symptoms.
Post-treatment and secondary resistance rates
The prevalence of post-treatment resistance
(detected after unsuccessful H. pylori eradication
regardless of susceptibility status of the strain
before treatment) and that of secondary resistance,
defined as resistance acquired during therapy by
previously susceptible isolates, were assessed in
337 isolates from six centers within five countries
[19,20,25,27,28] (pers. comm.: G. Gosciniak; S.
Kalenic; L. Boyanova; A. Vcev). The data encom-
pass the resistance rates in H. pylori after failure of
eradication using different triple or double treat-
ment regimens in separate centers (Table 1).
R E S U L T S
Prevalence of primary H. pylori resistance
Overall mean rates of primary H. pylori resistance
in 1998–2000 are listed in Table 2. During the last 3
years, there were no significant differences in
resistance rates to metronidazole or clarithromycin
between centers situated in central versus eastern
countries (P> 0.10) and between those in northern
versus southern countries (P> 0.20). Although, in
1996, all H. pylori isolates were metronidazole
susceptible in centers in Slovenia and no clarithro-
mycin resistance was found in six centers within
three countries, the susceptibility patterns have
changed since 1998. During the last 3 years, metro-
nidazole resistance was found everywhere, ran-
ging from 18.5% to 56.6% (and to 62.5% in one
center using a disk diffusion method); and clari-
thromycin resistance was observed in all but one
center. Resistance rates to clarithromycin varied
widely from 0% to 3.7% to 14.4% (and to 18.7% in
one center using a disk diffusion method).
From 1998, resistance to amoxicillin, ciproflox-
acin and tetracycline was found only in centers in
the southeastern part of Europe. In one center,
amoxicillin resistance was observed only in 1996
and not in 1997–98; and in another center resis-
tance to tetracycline and ciprofloxacin was found
in 1997 and not in the following 2 years. When
present, resistance to amoxicillin, ciprofloxacin
and tetracycline was rare, with mean rates for
centers in separate countries ranging from 1% to
4.3% for amoxicillin, 3.3% to 6.9% for tetracycline,
and 5.2% to 6.2% for ciprofloxacin. From 1998, the
overall mean resistance prevalences for amoxicil-
lin 0.5 mg/L, ciprofloxacin 1 mg/L and tetracy-
cline 4 mg/L, detected by both an agar dilution
method and E test, were 0.5% (including four of
888 isolates), 3.3% (nine of 270 isolates), and 1%
(six of 606 isolates), respectively. In addition, resis-
tance to amoxicillin, ciprofloxacin and tetracycline
was detected in 4.3% (five of 115 isolates), 5.2% (six
of 115 isolates) and 6.9% (eight of 115 isolates),
respectively, but only by modified disk diffusion
methods.
Evolution of primary H. pylori resistance
With regard to ten centers within five countries,
primary metronidazole resistance increased sig-
nificantly from 30.5% to 36.4% (P< 0.05) in the
group as a whole between 1996–97 and 1998–2000,
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while resistance rates to other agents and com-
bined resistance to metronidazole and clarithro-
mycin were relatively stable (Figure 1). A
significant increase in primary metronidazole
resistance was detected in centers in Russia,
Slovenia and Croatia, and was not found in those
in Bulgaria and Poland. Clarithromycin resistance
increased markedly only in one center in Moscow.
The same trends in evolution of resistance were
observed when the prevalence was recalculated
Table 2 Primary resistance rates of H. pylori in 1998–2000
Antimicrobial agent
and methods
No. of
centers
No. of
countries
No. of
strains
Mean rate
(%) of resistance 95% CI
All methodsa
Metronidazole 18 10 1371 37.9 35.3–40.5
Clarithromycin 18 9 1337 9.5 7.9–11.1
Amoxicillin 17 8 1003 0.9 0.3–1.5
Tetracycline 9 6 721 1.9 0.9–2.9
Ciprofloxacin 8 5 385 3.9 2.0–5.8
Metronidazole þ
clarithromycin
8 5 754 6.1 4.4–7.8
Agar dilution method
Metronidazole 7 5 824 34.5 31.2–37.8
Clarithromycin 5 3 705 9.5 7.3–11.7
Amoxicillin 5 3 463 0.6 0–1.3
Tetracycline 5 3 456 1.3 0.3–2.3
Ciprofloxacin 3 2 182 4.9 1.8–8.0
Metronidazole þ
clarithromycin
5 3 475 6.7 4.7–9.0
E test
Metronidazole 7 5 378 34.7 29.9–39.5
Clarithromycin 7 9 378 8.7 5.9–11.5
Amoxicillin 7 8 378 0.3 0–0.8
Tetracycline 2 6 150 0 0–1.3
Ciprofloxacin 4 5 88 0 0–2.1
Metronidazole þ
clarithromycin
1 5 196 4.6 1.7–7.5
aAgar dilution method, E test and modified disk diffusion method.
Figure 1 Incidence of mean overall primary H. pylori resistance in 1996–2000. MTZ, metronidazole; CLA, clarithromycin;
AMX, amoxicillin; TET, tetracycline; CIP, ciprofloxacin; METþCLA, metronidazole and clarithromycin.
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only for the years at the beginning and end of
studies in different centers.
Resistance patterns in children and adult
patients since 1998
In all centers within Poland, Greece and Bulgaria,
metronidazole resistance was slightly more pre-
valent in adults than in children (39% versus
31.2%, P> 0.05), significant differences being
found only in Bulgaria (Figure 2). Reverse trends
were observed for clarithromycin resistance
(Figure 3). No significant differences were present
between pediatric and adult patients in the
group of centers as a whole and nor in separate
institutions.
The mean prevalences of H. pylori resistance in
children were: metronidazole 31.2% (95% CI: 25.8–
36.6%), clarithromycin 11.7% (7.9–15.5%), amoxi-
cillin 0.7% (0–1.7%), tetracycline 1.2% (0–2.8%),
ciprofloxacin 1.8% (0–3.8%), and metronidazole–
clarithromycin 5.3% (2.5–8.1%).
Post-treatment and secondary resistance rates
The overall mean rates of post-treatment and
secondary H. pylori resistance were: 56.7% (95%
CI: 47.8–65.6%) and 56.2% (38.7–73.7%) for
Figure 2 Resistance of H. pylori to metronidazole in children versus adults in 1998–2000.
Figure 3 Primary H. pylori resistance to clarithromycin in children versus adults in 1998–2000.
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metronidazole, and 11.9% (7.6–16.2%) and 3.8%
(0.8–6.8%) for clarithromycin, respectively. Amox-
icillin resistance was found in 1.7% (95% CI:
0–4.1%) of all isolates after treatment failure
(Figure 4).
D I S C U S S I O N
In the east of Europe, the overall mean rate of
primary resistance of H. pylori to metronidazole is
considerable and that to clarithromycin is similar
or slightly higher than that in most western coun-
tries [1,5]. Several reports have focused on the
discrepancy, usually around 10–22%, between
results for metronidazole obtained by agar dilu-
tion and those obtained by other techniques
[2,29,30]. Me´graud has recommended the use of
an agar dilution method for metronidazole,
whereas any technique seems acceptable for clar-
ithromycin [4]. In this study, when only results of
the agar dilution method were taken into account,
the global primary resistance rate to metronida-
zole since 1998 was similar (34.5%) to that obtained
by E test (34.7%, P> 0.20) and significantly lower
than the resistance prevalence evaluated by disk
diffusion methods (42%, P< 0.02). However, addi-
tional national, regional and methodological fac-
tors (e.g. incubation of 3–5 days in one center) may
be associated with the higher resistance preva-
lence found by those who used modified disk
diffusion methods.
Although it is generally accepted that clari-
thromycin 1 mg/L and metronidazole 8 mg/L
correspond to resistance breakpoints for H. pylori
[1,30,31], MIC interpretive standards for other
antimicrobial agents are still lacking. Therefore,
the resistance breakpoint for amoxicillin (0.5 mg/
L) was chosen according to cut-off values used in
the multicenter study of Glupczynski et al. [5] and
other data [30]. A tetracycline breakpoint of 4 mg/
L was used, as this concentration is recommended
by the NCCLS [32] for determining susceptible
strains in anaerobic microbiology. The cut-off level
for ciprofloxacin (1 mg/L) was chosen because
sensitive H. pylori strains have exhibited
MICs 0.5 mg/L and resistant strains have shown
MICs> 2 mg/L [33]. Disk diffusion methods are
usually considered inappropriate for slow-grow-
ing bacteria, because the gradient of drug concen-
tration in agar after prolonged incubation is not
reproducible. However, this technique seems
applicable for testing the susceptibility of H. pylori
to antibiotics when there is a clearly bimodal
population (e.g. clarithromycin) [4]. Several
authors have reported the modified disk diffusion
method to be a reliable technique for H. pylori
susceptibility testing, with inhibitory zones indi-
cating resistance being <16 mm for metronidazole
and20 mm for clarithromycin [34,35]. The break-
points for H. pylori resistance to clarithromycin
were 15 mm in most centers and 20 mm in one
center, the latter cut-off value being more reliable
according to a recent study [35]. As different
interpretive inhibitory zone diameters and differ-
ent supporting media were used in several centers
to determine H. pylori resistance to clarithromycin,
Figure 4 Post-treatment and secondary H. pylori resistance rates. MTZ, metronidazole; CLA, clarithromycin.
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tetracycline and ciprofloxacin, the results obtained
by the disk diffusion technique must be inter-
preted with caution.
The problem of combined H. pylori resistance is
of utmost importance, as the treatment efficacy of
triple regimens may be compromised [36,37]. The
prevalence of double primary resistance to metro-
nidazole and clarithromycin was worrying and
oscillated around 4–6% in most centers, ranging
from 0% to 9.5% [9,11,16,18] (pers. comm.: G.
Gosciniak; L. Boyanova; K. Ivanova and M. Mar-
ina; E. Rozynek and D. Dzierz˙anowska). Although
rare, primary resistance to other drugs, such as
amoxicillin, ciprofloxacin and tetracycline, was
detected in several centers. In centers within
Slovenia and Lithuania, H. pylori isolates exhibit-
ed a low prevalence of resistance to all drugs
studied.
A high prevalence of clarithromycin resistance
was detected in children at centers in Poland from
1998 and could be related to the actual macrolide
consumption. Following the introduction of the
newer macrolides in 1992–95 in this country, the
consumption of these drugs (in kilograms of active
substance) has increased more than threefold from
1996 to 2000. However, this association was not
detected with children in Bulgaria, because the
national consumption of macrolides (0.34 DDD/
1000 inhabitants/day) and that of newer macro-
lides (0.08), such as roxithromycin, clarithromycin
and azithromycin, was low in 1999. Recent studies
involving children in France and Spain have
shown considerable clarithromycin resistance
rates in H. pylori in 28.3% and 21% of isolates,
respectively [38,39].
Antimicrobial resistance rates in eastern Europe
vary enormously among centers. This could reflect
variables, such as regional or inter-hospital differ-
ences in protocol or procedures and national or
regional differences in drug consumption, as well
as methodological factors. In addition, consider-
able variations in post-treatment resistance rates to
metronidazole (17.5–87.9%) and clarithromycin
(1.8–50%) were found between centers as a result
of different triple or double regimens used for H.
pylori eradication.
From 1996, a marked increase in the overall
mean prevalence of H. pylori resistance was found
only for metronidazole. However, the patterns of
resistance evolution exhibited considerable differ-
ences among the centers studied. Global resistance
patterns of H. pylori in children are worrying and
worth extensive evaluation in multiple centres
throughout Europe.
Constant monitoring of both patterns and evo-
lution of H. pylori resistance in eastern Europe,
based on a complete standardization of suscept-
ibility testing methods and interpretive break-
points, is needed in order to counteract the
serious consequences of H. pylori infection.
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